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A novel pathogenic variant in OSBPL2
linked to hereditary late-onset deafness in
a Mongolian family
Ningjin Wu1,2†, Husile Husile1,3†, Liqing Yang1,3†, Yaning Cao4, Xing Li5, Wenyan Huo1,3, Haihua Bai3,5,
Yangjian Liu6* and Qizhu Wu1,3*
Abstract
Background: To investigate the clinical features and the underlying causal gene of a family with hereditary late-
onset deafness in Inner Mongolia of China, and to provide evidence for the early genetic screening and diagnosis
of this disease.
Methods: Family data were collected to draw a pedigree. Audiological testing and physical examination of the
family members were conducted following questionnaire. Genomic DNA was extracted from peripheral blood of 5
family members (3 patients and 2 normal control) and subjected to whole genome sequencing for identifying
deafness casual genes. The pathogenic variant in the deafness gene was further confirmed by Sanger sequencing.
Results: The family is composed of a total of 6 generations, with 53 traceable individuals. In this family,19 of them
were diagnosed with post lingual deafness with the age of onset between 10 and 40 years, displaying delayed and
progressive hearing loss. Patients with hearing loss showed bilateral symmetry and mild to severe sensorineural
deafness. The pattern of deafness inheritance in this family is autosomal dominant. Whole genome sequencing
identified a novel pathogenic frameshift mutation, c.158_159delAA (p.Gln53Arg fs*100) in the gene OSBPL2
(Oxysterol-binding protein-related protein 2, NM_144498.2), which is absent from genomic data of 201 unrelated
normal subjects. This pathogenic variant was further validated by Sanger sequencing, and was found to co-
segregate in this family.
Conclusions: Whole genome sequencing identified a two-nucleotide deletion in OSBPL2 (c.158_159delAA) as the
pathogenic variant for deafness in the family. Our finding expands the mutational spectrum of OSBPL2 and
contributes to the pathogenic variant list in genetic counseling for deafness screening.
Keywords: Hereditary late-onset deafness, Whole genome sequencing, OSBPL2 gene, Co-segregation
Background
Deafness is a defect of the human auditory system, and
it is also one of the common diseases that seriously af-
fects human health. Without intervening, the hearing
loss in children could lead to delayed speech, difficulty
in reading, and lack of confidence, severely affecting
their growth and social skills. The deafness could be a
result of genetic, environmental and other unknown fac-
tors, with genetic factors contributing to the majority
cases of deafness. Studies have shown that about 50 to
60% of hearing loss is inherited [1]. The inheritance pat-
tern of deafness includes autosomal dominant inherit-
ance, autosomal recessive inheritance and X-linked [2].
Based on whether there are other systemic or organ dis-
orders, clinical deafness can be divided into
non-syndromic deafness and syndrome deafness [3].
Non-syndromic hearing loss (NSHL) constitutes about
70% of congenital hereditary deafness while syndromic
hearing loss (SHL) accounts for the other 30%. In devel-
oped countries, nearly 80% of the non-syndromic
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deafness is attributed to genetic factors, of which 75–
80% is autosomal recessive, 10–15% is autosomal dom-
inant, and the rest is X-linked or mitochondrial [4].
Among these, autosomal dominant hereditary deafness
(also known as autosomal dominant non-syndromic sen-
sorineural hearing loss, DFNA) mostly displays postlin-
gually, late-onset and progressive sensorineural hearing
loss [5].
Next-generation sequencing has been demonstrated to
be a powerful technology on identifying mutations of
Mendelian diseases [6]. In recent years, the application
of next-generation sequencing technology has greatly ac-
celerated the identification of new rare disease genes [7].
In this study, we characterized the clinical phenotype
of a Mongolian family with hereditary late-onset deaf-
ness. To identify the causal gene for deafness in this
family, we applied whole genome sequencing analysis to
pinpoint OSBPL2 (Oxysterol-binding protein-related
protein 2) as the disease gene. This is the third family re-
ported with hearing loss due to OSBPL2 frameshift
variants.
Methods
Family data and sample collection
The affected family with 19 cases of deafness (12 males
and 7 females) in 53 traceable members have been living
in Inner Mongolia of north China for 6 generations
(Fig. 1). Audiology examination and physical
examination were performed to confirm the clinical phe-
notypes. Medical history and life habit investigation of
this family were also collected to rule out the possibility
of environmentally associated deafness. Peripheral blood
(10 ml) of each family member was drawn into two
EDTA anticoagulant tubes and stored at the Institute of
Genomic and Genetic Diseases for the Mongolian of
Inner Mongolia University for the Nationalities for fur-
ther study. The project was approved by the ethics com-
mittee of the Affiliated Hospital of Inner Mongolia
University for the Nationalities. All participants signed
informed consent.
Clinical audiology test
Pure tone audiometry, tympanogram and acoustic reflec-
tion domain of the family members were examined in
the Affiliated Hospital of Inner Mongolia Medical Uni-
versity to assess the hearing condition, middle ear con-
duction and nature of the disease.
The criterion of hearing loss phenotype
As suggested by the proposal of EU hearing program [8],
hearing loss was classified according to the average hear-
ing threshold of the speech frequency: Normal (auditory
threshold <20 dB HL), mild (auditory threshold of 20 -
40 dB HL), moderate (auditory threshold of 41 - 70 dB
HL), severe (auditory threshold for 71 - 95 dB HL) and
profound (auditory threshold>95 dB HL). According to
Fig. 1 Pedigree and genotypes of the late-onset deafness family. V-9 is the proband. +/−: heterozygous for OSBPL2, +/+: wild type for OSBPL2.
Members with genotypes noted were recruited for this study
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the frequency distribution of hearing loss, it is divided
into the hearing loss of high frequencies (2 - 8 kHz), low
frequencies (less than or equal to 0.5 kHz), mid frequen-
cies (0.5 - 2 kHz) and extended high frequencies (greater
than 8 kHz).
Gene detection
Whole genome sequencing: the whole genome sequen-
cing and subsequent bioinformatic analysis of 5 family
members, including 3 affected subjects and 2 normal
controls, was carried out by Novogene Bioinformatics
Institute, Beijing, China(Additional file 1: Tables S1–S2).
Sanger sequencing validation: the Sanger sequencing
was used to verify the co-segregation of candidate patho-
genic variant in members of the family with the deafness
phenotype. The primers for PCR amplification of the
pathogenic variant are: OSBPL2 forward primer, 5
‘-TCAGGTCCAGCGAAAATG-3, and OSBPL2 reverse
primer, 5’ -TTAGATGGGGAAAGGCAC-3′. The reac-
tion conditions of PCR amplification are described as
follows: 10 min pre-denaturation at 95 °C, 45 s denatur-
ation at 94 °C, 45 s annealing at 50 °C, 45 s extension at
72 °C, for 35 cycles, and 72 °C extension 8min after the
end of the reaction. The PCR products were purified
and sequenced by BGI-Beijing, Shenzhen, China.
Blood lipid detection
The blood lipids including triglyceride and total choles-
terol of the affected subjects and control individuals
were tested at the Affiliated Hospital of Inner Mongolia
Medical University. The Statistics of blood lipids was an-




The clinical manifestations of all deafness affected sub-
jects were delayed hearing loss with the age of onset be-
tween 10 and 40 years old and a history of tinnitus but
not vestibule dysfunction. All affected subjects had no
history of ototoxic drug use, noise exposure, or mental
disorders. All hearing loss was post lingual, and the se-
verity increased with age. Hearing tests were diagnosed
as bilaterally symmetric, mild to severe sensorineural
Fig. 2 Pure tone audiometry of representative subjects. Both the left (blue symbol Χ, >, ↘) and right (red symbol Ο, <, ↙) ears of subjects were
tested for their response to frequency (Hz, X-axis) and intensity (dB, Y-axis). Χ and Ο denote gas conduction; >and < denote bone conduction;
↘and ↙ denote no response; Audiograms of three different patients (V-7, V-9, V-11) are shown in b, c, d respectively and normal member (V-6) is
shown in a. The sensorineural hearing loss ranges from mild (V-11), to moderate (V-9), and to severe (V-7)
Wu et al. BMC Medical Genetics           (2019) 20:43 Page 3 of 7
hearing loss (Fig. 2). The results of tympanometry were
normal (Additional file 2: Figure S1). Each generation of
the family has affected members, both male and female,
a characteristic of autosomal dominant deafness.
Whole genome sequencing results
Our initial attempt with exome capture sequencing on
127 known deafness genes failed to identify any patho-
genic mutations (Additional file 1: Table S3).To identify
the causal gene responsive for the hearing loss in this
family, we conducted whole genome sequencing of 5
family members, including 3 affected subjects (IV-2,
IV-9, and V-9) and 2 normal controls (IV-14 and V-6).
Linkage analysis using Perl based Merlin tools was per-
formed combining high throughput sequencing data in
the family and the allelic frequency of Chinese popula-
tion (CHB) in the HapMap database, and known SNP
marker. Several linkage candidate regions were detected
even though with low LOD score around 1.5 (Fig. 3).
All the SNPs and indels (insertion and deletion) de-
tected by whole genome sequencing were filtered
through 1000 Genome Project (ftp://ftp.1000genomes.
ebi.ac.uk/vol1/ftp). The candidate genes were further
screened by the in house precision algorithm of Novo-
gene (Beijing, China) combined with the sequencing re-
sults and a variety of databases including Single
Nucleotide Polymorphism database (dbSNP), Exome Ag-
gregation Consortium (ExAC), Functional annotation of
genetic variants from high-throughput sequencing data
(esp6500siv2_all), ALL variants dataset of 1000 Genomes
Project released in Aug 2015 (1000g2015aug_all). We
then narrowed down the list of candidate genes to
OSBPL2, considering the disease genotype and pheno-
type association. A frameshift mutation in OSBPL2,
c.158_159delAA, was detected after whole genome
Fig. 3 Genetic analysis of deafness family. a Linkage analysis detects four loci with LOD score around 1.5, red arrow points to the locus of
OSBPL2. b OSBPL2 is located on chromosome 20q13.33 (red bar). c The OSBPL2 deletion is detected in exon 3 (red box). d Sequencing
chromatograms of OSBPL2 shows a heterozygous frameshift deletion c.158_159delAA (deleted nucleotides are boxed) in DNA from affected
patients (right) as compared to that from control (left). e The c.158_159delAA (p.Gln53Arg fs*100) mutation of OSBPL2 occurs before the oxysterol
binding domain. Other published mutations on OSBPL2 were also shown
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sequencing which seems to be the pathogenic variant re-
sponsive for the hearing loss in this Mongolian family.
OSBPL2 localizes 20q13.33 (www.genome.ucsc.edu),
consistent with the peak detected on the chromosome
20 in linkage analysis (Fig. 3).
Frameshift mutation validation by sanger sequencing
We next sought to confirm the frameshift mutation
(c.158_159delAA) on OSBPL2 associated with the hear-
ing loss in this family. The target fragment spanning the
frameshift mutation (c.158_159delAA) was amplified by
PCR and purified with agarose gel electrophoresis (426
bp). The PCR products were then sequenced by Sanger
sequencing. We chose to amplify 13 samples for Sanger
sequencing validation. The frameshift mutation in
OSBPL2, c.158_159delAA, co-segregated in the family
and was only detected in patients with hearing loss (Fig.
1). In addition, this frameshift mutation in OSBPL2,
c.158_159delAA, was negative from another 201 normal
individuals who had been sequenced in our previous
work (Chinese National Genebank CNSA, https://db.
cngb.org/cnsa), further confirming that this frameshift
mutation is the pathogenic variant leading to hearing
loss in this Mongolian family.
Blood lipid detection
OSBPL2 encodes a receptor and is mainly involved in
regulation of cellular cholesterol transport and lipid me-
tabolism. To find out whether the frameshift mutation
in OSBPL2 gene affects lipid metabolism, we next tested
the blood lipid level in members of this family with the
confirmed genotype for OSBPL2. The results showed
that the serum lipid levels of individuals with hearing
loss are all within normal range, and are
indistinguishable from those of normal individuals as de-
termined by the p value (Table 1), suggesting the redun-
dancy of other OSBP proteins in compensating the
defect of OSBPL2 in controlling blood lipid metabolism.
However, this hypothesis needs to be further tested by
knocking out of individual OSBP genes in mouse model
or cell lines.
Discussion
Hereditary deafness is a common form of severe hearing
impairment. In this study, a new frameshift mutation,
c.158_159delAA (p.Gln53Arg fs*100) in OSBPL2
(NM_144498.2), was found in a family with hereditary
late-onset non-syndromic deafness by whole genome se-
quencing, followed by confirmation with Sanger sequen-
cing. This frameshift mutation (c.158_159delAA) of
OSBPL2 results in abnormal OSBPL2 protein product
with amino acid change starting from the 53rd amino
acid and right before the sterol binding pocket on
OSBP-related domain (aa75–470, http://pfam.xfam.org/
protein/Q9H1P3), completely abolishing the binding
capacity of mutant protein to sterol [9].
OSBPL2 encodes a receptor with high affinity to oxi-
dized sterols belonging to a family of oxysterol binding
proteins (ORPs), which play an important function in
sterol/lipid transport and metabolism, cell activity regu-
lation and signal transduction. The pathogenic variants
in the OSBP/ORP family members have been shown to
cause diseases (such as dyslipidemia, cardiovascular dis-
ease) [10–12]. Pathogenic variant in the OSBPL2 gene
has also been shown to cause autosomal dominant her-
editary hearing loss. Genetic analysis of a Chinese auto-
somal dominant deafness family identified a frameshift
mutation in OSBPL2 gene (c.153_154delCT) providing
Table 1 The blood lipid level in members of this family
No. Individual Age (ys.) Age of onset(ys.) HDL-C (mmol/L) TCh (mmol/L) TG (mmol/L) LDL-C (mmol/L)
1 IV-2 61–70 20 1.25 4.28 1.08 3.25
2 IV-9 61–70 14 1.30 5.50 1.07 3.80
3 IV-12 61–70 27 1.40 3.80 1.55 2.86
4 V-7 41–50 12 1.00 3.60 0.71 2.13
5 V-9 41–50 17 1.15 4.83 0.66 2.35
6 V-11 31–40 22 1.00 4.60 1.74 3.54
7 VI-5 21–30 19 1.14 3.22 0.59 1.81
8 IV-14 51–60 non affected 1.29 4.18 1.53 2.69
9 VI-6 21–30 non affected 1.70 3.90 0.90 2.00
10 V-6 41–50 non affected 1.10 5.90 1.68 3.80
11 V-13 31–40 non affected 1.50 5.24 1.02 3.25
12 VI-1 21–30 non affected 1.40 4.70 1.56 3.10
13 VI-4 11–20 non affected 1.65 5.50 1.47 3.50
Reference value: HDL-C: 0.9~1.7 mmol/L; TCh: 2.9~6.0 mmol/L; TG: 0.9~1.7 mmol/L; LDL-C: 2~4.11 mmol/L
The p value between affected and control group: HDL-C: 0.184; TCh: 0.128; TG: 0.259; LDL-C: 0.137. p < 0.05 is considered to be significant
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the first evidence that OSBPL2 is associated with the oc-
currence of non-syndromic deafness [13]. Subsequently,
another frameshift mutation (c.141_142delTG) in the
OSBPL2 gene was also found in a German NSHL family,
further confirming that OSBPL2 is a new deafness gene
[14]. Interestingly, protein sequence change p.Gln53Arg
fs*100 on OSBPL2 resulting from the frameshift muta-
tion c.158_159delAA in this study is coincidentally iden-
tical to the reported c.153_154delCT [13].
Cholesterol is an important molecular component of
mammalian plasma membrane and an important regula-
tor for the properties of membrane. Recently, changes in
cochlear cholesterol levels were shown to modulate the
amplitude of distortion product otoacoustic emissions
(DPOAEs), consistent with changes in electromotility
[15]. Some studies have tried to explain the role of mem-
brane cholesterol in the physiology of hair cells [15]. A
recent study tried to connect the relationship between
hearing loss and high cholesterol, and found that hearing
level seems to be affected by hyperlipidemia [16].
OSBPL2 is mainly involved in the physiological func-
tions of cell cholesterol transport and lipid metabolism.
Over expression of OSBPL2 in mammalian cells has
been reported to alter cholesterol synthesis, cholesterol
esterification and cholesterol efflux [17]. In this study,
blood lipid examination found that serum lipid levels
from both non affected and affected individuals are
within the normal range and are not different by statis-
tics. This could be due to the redundant expression of
other OSBP genes and deficiency of a copy of OSBPL2
gene does not shift the homeostasis of cholesterol me-
tabolism in the digestive system.
OSBPL2 is highly expressed in the inner and outer hair
cells of the mouse cochlea [13, 14] and cholesterol level
in hair cells seems to affect hearing [16]. It is plausible
that OSBPL2 is the major OSBP gene expressed in hair
cells, which could be very sensitive to the dosage of
OSBPL2. A frameshift mutation in the gene encoding
OSBPL2 might completely block the transport and me-
tabolism of cholesterol in the cochlear hair cells and
therefore results in hearing loss. However, this hypoth-
esis needs to be tested by examining the expression pat-
tern of other OSBP/ORP family members in the cochlea
as well as by studying animal models with OSBPL2
deficiency.
Conclusion
A frameshift deletion in OSBPL2 (c.158_159delAA) was
identified by whole genome sequencing as the patho-
genic variant of a Mongolian family hereditary late-onset
deafness. Our finding extends the pathogenic variant
spectrum of OSBPL2 in autosomal dominant hereditary
deafness (ADNSHL) and provides the genetic basis to
include OSBPL2 in genetic counseling for deafness
screening.
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